GLP-1 and Cosmetic Surgery: Hold & Recovery (2026)

If you take Ozempic, Wegovy, Mounjaro, Zepbound or another GLP-1 and you have a facelift, tummy tuck, liposuction, breast surgery or other elective cosmetic procedure booked, two separate worries get mixed together online: do I have to hold the drug before anesthesia, and will being on a GLP-1 slow my healing afterward? They deserve different answers. The anesthesia concern is real and evidence-based: GLP-1 drugs slow gastric emptying, so your stomach can still hold food and fluid after normal fasting, and in pooled data of 262,018 patients GLP-1 users had about 4.5× the odds of retained gastric contents under sedation (Baig 2025 ^[1]). The recovery concern — that GLP-1-driven muscle/lean-mass loss and reduced eating could impair wound healing — is largely theoretical and extrapolated, not demonstrated in randomized surgical trials. This article separates the two so you can plan with your surgeon and anesthesiologist instead of guessing. For the general version, see holding a GLP-1 before surgery and the ASA guidance.

The honest summary

• The aspiration concern is real and evidence-based. Slowed gastric emptying leaves food and fluid in the stomach after normal fasting. Pooled across 23 studies and 262,018 patients, GLP-1 users had about 4.5× the odds of retained gastric contents under sedation (Baig 2025^[1]). That matters because most cosmetic procedures use sedation or general anesthesia.
• The ASA said hold weekly drugs about a week before (June 2023). The American Society of Anesthesiologists advised skipping daily-dosed GLP-1s on the day of the procedure and stopping weekly-dosed ones — Ozempic, Wegovy, Mounjaro, Zepbound — roughly a week before elective procedures (Hashash 2024^[2]; Kindel 2025^[3]).
• The 2024 multisociety consensus added a middle path. It favored shared decision-making plus an option to use a clear-liquid diet for at least 24 hours before and/or a rapid-sequence anesthesia technique, rather than reflexively cancelling (Kindel 2025^[3]).
• Plastic-surgery-specific guidance mirrors this. A 2025 review for plastic surgeons recommends risk-stratified management — continue with a clear-liquid prep for low-risk patients, hold (weekly >1 week, daily 24-48 h) for higher-risk ones (Davila Diaz 2025^[4]).
• The wound-healing worry is theoretical. GLP-1s cause real lean-mass loss (about 40% of weight lost was lean tissue in STEP 1; Wilding 2021^[8]) and can cut protein intake. Because protein supports collagen and tissue repair (Quain 2015^[9]), people infer a healing penalty — but no randomized cosmetic-surgery trial has shown GLP-1 use impairs wound healing. Treat it as a nutrition issue to manage, not a proven harm.
• Bottom line: don't decide alone. Coordinate the hold timing with your anesthesiologist and the surgeon, and prioritize protein around surgery. Follow your facility's written instructions.

Angle 1: holding a GLP-1 before the procedure (the anesthesia question)

GLP-1 receptor agonists slow how fast the stomach empties — that delayed emptying is part of how they blunt appetite. The catch is that your stomach can still hold solids or fluid even after the standard “nothing to eat” fasting window. Cosmetic procedures — facelifts, rhinoplasty, breast augmentation, abdominoplasty, liposuction, brachioplasty — are almost always done under sedation or general anesthesia, and a stomach that isn't empty creates a risk of regurgitating and aspirating contents into the lungs. The first hard signal came from a retrospective study of 404 upper-endoscopy patients: those who'd taken semaglutide within 30 days had retained gastric contents 24.2% of the time versus 5.1% of non-users — an adjusted odds ratio of about 5.2 — even though most had stopped roughly 10 days before (Silveira 2023^[5]). A prospective gastric-ultrasound study in volunteers newly started on semaglutide found the same direction of effect (Sherwin 2023^[6]).

Those single-center findings have since been pooled. Baig 2025^[1] combined 23 studies and 262,018 patients and found GLP-1 users had about 4.5× the odds of retained gastric contents (OR 4.54) — but, importantly, no significant increase in aspiration pneumonia (OR 0.96). In other words, the “food in the stomach” finding is robust; the leap from that to actual lung injury is not yet well supported by outcome data. That gap is exactly why the specialties disagreed about how aggressively to hold the drug.

What the guidance says for elective cosmetic procedures

In June 2023 the American Society of Anesthesiologists issued consensus guidance recommending patients hold their GLP-1 before elective procedures: skip the dose on the day of the procedure for daily-dosed agents, and stop weekly-dosed agents (semaglutide as Ozempic/Wegovy, tirzepatide as Mounjaro/Zepbound) about a week beforehand. The 2024 multisociety guidance — written jointly by anesthesiology, gastroenterology, and bariatric-surgery groups — tried to reconcile the debate (Kindel 2025^[3]). It recommended decisions be based on shared decision-making balancing the need for the drug against individual aspiration risk, and offered a middle path: for patients where delayed emptying is a concern, a clear-liquid diet for at least 24 hours before “as performed in patients undergoing colonoscopy and bariatric surgery,” instead of or in addition to holding the drug. For higher-risk cases it suggested point-of-care gastric ultrasound on the day, treating the patient as “full stomach” with a rapid-sequence anesthesia technique, or rarely rescheduling.

Plastic surgery has its own emerging literature on this. A 2025 review aimed at plastic surgeons (Davila Diaz 2025^[4]) endorses a risk-stratified approach: low-risk patients (asymptomatic, on stable daily dosing) can often continue the drug with mitigations like a 24-hour clear-liquid diet, while higher-risk patients (active dose escalation, GI symptoms, weekly formulations) should discontinue — weekly agents more than a week before surgery, daily agents 24-48 hours before. It notes that prospective evidence shows a higher prevalence of residual gastric content in GLP-1 users, supporting aspiration precautions and individualized management. The practical message for cosmetic patients is the same as for any elective surgery: the hold decision is your anesthesiologist's and surgeon's to make with you, and it depends on the specific drug, dose schedule, symptoms, and facility protocol.

Angle 2: will a GLP-1 slow my recovery? (the wound-healing question)

This is where online claims outrun the evidence. The reasoning behind the worry is legitimate on its face. First, GLP-1 weight loss is not all fat. In the STEP 1 exploratory body-composition analysis, semaglutide users lost meaningful lean (muscle) mass — roughly 40% of the total weight lost was lean tissue, measured by DXA (Wilding 2021^[8]). Second, the same appetite suppression that drives the weight loss can cut overall food intake, including protein. Third, protein and amino acids genuinely matter for healing: once a wound exists, protein demand rises to support collagen synthesis and tissue repair, and inadequate protein is associated with slower, lower-quality healing (Quain 2015^[9]; Childress 2008^[10]). Stack those together and it is reasonable to ask whether someone in an active catabolic, lower-protein state heals an incision as well.

But here the honesty has to be explicit: that chain of reasoning is extrapolation, not a demonstrated effect. There is no randomized controlled trial showing that taking a GLP-1 impairs surgical wound healing or worsens cosmetic-surgery outcomes. The wound-healing/protein literature that supports the concern (Quain 2015^[9]; Childress 2008^[10]) studied malnutrition and chronic or pressure wounds in general patients — not GLP-1 users undergoing elective cosmetic procedures. The lean-mass data (Wilding 2021^[8]) describe body composition over months of weight loss, not perioperative healing. And the dedicated 2025 plastic-surgery review focuses entirely on perioperative aspiration risk — it does not document wound-healing or nutritional harm from GLP-1 use (Davila Diaz 2025^[4]). So the right framing is: the ingredients of a theoretical concern are real, but the outcome — slower healing on a GLP-1 — has not been shown.

What follows from that is a nutrition-management stance, not a reflexive “stop the drug to heal.” The same lean-mass-preservation playbook used outside surgery applies: prioritize adequate protein and resistance/strength activity to protect muscle during weight loss. For the underlying evidence, see muscle and lean-mass loss on GLP-1s and how to protect it and the muscle-loss-prevention protocol. Around a cosmetic procedure, that translates into hitting protein targets in the weeks before and after surgery, and flagging to your surgeon if appetite suppression is keeping your intake very low — because real, severe undernutrition genuinely does impair healing, regardless of the cause.

What this means for you — the practical upshot

• Don't stop your GLP-1 on your own. The right hold plan depends on the drug, your dose schedule, why you take it, your GI symptoms, and your facility's protocol — which vary. Self-discontinuing can also worsen diabetes control.
• Tell BOTH the anesthesiologist/surgical facility AND your prescriber, well ahead. Name the exact drug (Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, etc.), your dose, and when you last took it. Ask: should I hold a dose, for how long, and should I extend a clear-liquid diet before the procedure?
• Expect a possible clear-liquid diet and/or anesthesia adjustment. Many teams now ask GLP-1 users for at least 24 hours of clear liquids before sedation, may use a rapid-sequence technique, or may check gastric ultrasound the day of (Kindel 2025^[3]; Davila Diaz 2025^[4]).
• Flag ongoing GI symptoms. Nausea, vomiting, bloating, or persistent fullness are the strongest predictors of retained stomach contents (Silveira 2023^[5]; Santos 2024^[7]). If you have them near your surgery date, say so — it may change the plan.
• Prioritize protein around surgery. Because GLP-1 weight loss includes lean mass (Wilding 2021^[8]) and protein supports tissue repair (Quain 2015^[9]), aim for adequate protein before and after — and tell your surgeon if appetite suppression is keeping your intake very low.
• Don't treat “GLP-1s slow healing” as established. It is a theoretical, extrapolated concern with no cosmetic-surgery trial behind it. Manage nutrition; don't panic or self-stop based on online claims.
• Follow YOUR facility's written instructions. Protocols genuinely differ; the consensus documents leave room for local judgment.

Bottom line

For elective cosmetic surgery, the two GLP-1 questions deserve different answers. The anesthesia/aspiration concern is real and evidence-based — GLP-1 users have roughly 4.5× the odds of food retained in the stomach under sedation (Baig 2025^[1]) — which is why the ASA and a 2024 multisociety consensus recommend an individualized plan that may include holding the drug (weekly agents about a week before, daily agents the day of or 24-48 h before) and/or an extended clear-liquid diet and anesthesia adjustments (Hashash 2024^[2]; Kindel 2025^[3]; Davila Diaz 2025^[4]). The wound-healing concern is different: GLP-1s do cause real lean-mass loss (Wilding 2021^[8]) and can reduce protein intake, and protein matters for repair (Quain 2015^[9]; Childress 2008^[10]) — but no randomized cosmetic-surgery trial has shown GLP-1 use impairs healing, so it remains theoretical and is best handled as a nutrition issue, not a reason to self-stop. The single safest move: coordinate the hold with your anesthesiologist and surgeon, prioritize protein, and follow your facility's written instructions.

This article is educational and is not medical advice. Every claim above is sourced to a peer-reviewed study, society clinical practice update, or multisociety consensus indexed in PubMed and verified against the live PubMed database before publication. Where a concern is theoretical or extrapolated rather than proven, the text says so explicitly. Coordinate your own pre- and post-operative plan with your prescriber, surgeon, and anesthesia team.